Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer
- PMID: 31197699
- PMCID: PMC6908777
- DOI: 10.1007/s11605-019-04230-z
Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer
Abstract
Background: Screening high-risk individuals (HRI) can detect potentially curable pancreatic ductal adenocarcinoma (PDAC) and its precursors. We describe the outcomes of high-risk individuals (HRI) after pancreatic resection of screen-detected neoplasms.
Methods: Asymptomatic HRI enrolled in the prospective Cancer of the Pancreas Screening (CAPS) studies from 1998 to 2014 based on family history or germline mutations undergoing surveillance for at least 6 months were included. Pathologic diagnoses, hospital length of stay, incidence of diabetes mellitus, operative morbidity, need for repeat operation, and disease-specific mortality were determined.
Results: Among 354 HRI, 48 (13.6%) had 57 operations (distal pancreatectomy (31), Whipple (20), and total pancreatectomy (6)) for suspected pancreatic neoplasms presenting as a solid mass (22), cystic lesion(s) (25), or duct stricture (1). The median length of stay was 7 days (IQR 5-11). Nine of the 42 HRI underwent completion pancreatectomy for a new lesion after a median of 3.8 years (IQR 2.5-7.6). Postoperative complications developed in 17 HRI (35%); there were no perioperative deaths. New-onset diabetes mellitus after partial resection developed in 20% of HRI. Fourteen PDACs were diagnosed, 11 were screen-detected, 10 were resectable, and 9 had an R0 resection. Metachronous PDAC developed in remnant pancreata of 2 HRI. PDAC-related mortality was 4/10 (40%), with 90% 1-year survival and 60% 5-year survival, respectively.
Conclusions: Screening HRI can detect PDAC with a high resectability rate. Surgical treatment is associated with a relatively short length of stay and low readmission rate, acceptable morbidity, zero 90-day mortality, and significant long-term survival.
Clinical trial registration number: NCT2000089.
Trial registration: ClinicalTrials.gov NCT02000089.
Keywords: Early detection; Pancreatic cancer; Screening; Surgical outcomes.
Similar articles
-
Laparoscopic versus open pancreatic resection for ductal adenocarcinoma: separate propensity score matching analyses of distal pancreatectomy and pancreaticoduodenectomy.BMC Cancer. 2021 Apr 9;21(1):382. doi: 10.1186/s12885-021-08117-8. BMC Cancer. 2021. PMID: 33836678 Free PMC article.
-
Asymptomatic Pancreatic Cancer: Does Incidental Detection Impact Long-Term Outcomes?J Gastrointest Surg. 2017 Aug;21(8):1287-1295. doi: 10.1007/s11605-017-3421-2. Epub 2017 Apr 10. J Gastrointest Surg. 2017. PMID: 28397027
-
Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.JAMA Surg. 2019 Jun 1;154(6):e190484. doi: 10.1001/jamasurg.2019.0484. Epub 2019 Jun 19. JAMA Surg. 2019. PMID: 30942874 Free PMC article.
-
Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A Systematic Review and Meta-Analysis.Gastroenterology. 2022 Mar;162(3):786-798. doi: 10.1053/j.gastro.2021.11.021. Epub 2021 Nov 20. Gastroenterology. 2022. PMID: 34813861
-
Total pancreatectomy for metachronous mixed acinar-ductal carcinoma in a remnant pancreas.World J Gastroenterol. 2014 Sep 7;20(33):11904-9. doi: 10.3748/wjg.v20.i33.11904. World J Gastroenterol. 2014. PMID: 25206298 Free PMC article. Review.
Cited by
-
The impact of pancreatic cancer screening on life expectancy: A systematic review of modeling studies.Int J Cancer. 2023 Apr 15;152(8):1570-1580. doi: 10.1002/ijc.34379. Epub 2022 Dec 14. Int J Cancer. 2023. PMID: 36444505 Free PMC article.
-
The German National Case Collection for Familial Pancreatic Carcinoma (FaPaCa)—Knowledge Gained in 20 Years.Dtsch Arztebl Int. 2021 Mar 12;118(10):163-8. doi: 10.3238/arztebl.m2021.0004. Dtsch Arztebl Int. 2021. PMID: 33531114 Free PMC article.
-
In-silico identification of therapeutic targets in pancreatic ductal adenocarcinoma using WGCNA and Trader.Sci Rep. 2024 Oct 7;14(1):23292. doi: 10.1038/s41598-024-74252-4. Sci Rep. 2024. PMID: 39375436 Free PMC article.
-
Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer.Clin Gastroenterol Hepatol. 2020 May;18(5):1161-1169.e5. doi: 10.1016/j.cgh.2019.10.036. Epub 2019 Oct 30. Clin Gastroenterol Hepatol. 2020. PMID: 31676359 Free PMC article.
-
Potential of artificial intelligence in the risk stratification for and early detection of pancreatic cancer.Artif Intell Surg. 2023;3(1):14-26. doi: 10.20517/ais.2022.38. Epub 2023 Mar 20. Artif Intell Surg. 2023. PMID: 37124705 Free PMC article.
References
-
- Clancy TE. Surgery for pancreatic cancer. Hematol Oncol Clin North Am 2015;29:701–16. - PubMed
-
- Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2019. CA Cancer J Clin 2019;69:7–34. - PubMed
-
- Corral JE, Mareth KF, Riegert-Johnson DL, et al. Diagnostic yield from screening asymptomatic individuals at high risk for pancreatic cancer: a meta-analysis of cohort studies. Clin Gastroenterol Hepatol 2019. PMID 29775792 - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous